Research·October 23, 2026 at 12:40 PM EDT·1 source
Novartis Multiple Sclerosis Pill Missed Expectations in Key Study
NVS -3.3%
NVS · last 30 trading days-1.8% since the news
News
What happened
- Novartis AG’s experimental multiple sclerosis pill prevented fewer relapses than expected in two late-stage trials.
- The results could give Roche Holding AG an advantage with a rival multiple sclerosis drug it is developing.
Why it matters
The study outcome may affect competitive positioning in the multiple sclerosis market and Novartis’s and Roche’s drug-development strategies.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 16Novartis scraps Fabhalta study in lupus nephritis
- EarlierOct 22Roche talks up Phase 3 success rate as it unveils pipeline cuts
- EarlierOct 23Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
- EarlierOct 23Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- First reported by BloombergOct 23Novartis Multiple Sclerosis Pill Missed Expectations in Key Study
Who is involved
Novartis Multiple Sclerosis Pill Missed Expectations in Key S…Novartis AGNVSRoche Holding AG
Company
Sources (1)
Related
- Oct 23 · Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Oct 23 · Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
- Oct 23 · Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
- Oct 22 · Roche talks up Phase 3 success rate as it unveils pipeline cuts
- Oct 16 · Novartis scraps Fabhalta study in lupus nephritis
- Oct 13 · Novartis quietly returns a key antibiotic to US market
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.